AustralieFrV1, Main, Exploration, bibRecord, 00DF54

Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells

Identifieur interne : 00DF54 ( Main/Exploration ); précédent : 00DF53; suivant : 00DF55

Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells

Auteurs : P. G. Gill [France] ; F. Vignon [France] ; S. Bardon [France, Australie] ; D. Derocq [France] ; H. Rochefort [France]

Source :

Breast Cancer Research and Treatment [ 0167-6806 ] ; 1987-10-01.

RBID : ISTEX:A0075C6D840A104E3B7DE3CDB1B824FDD9919626

English descriptors

Abstract

Summary: We have compared the effects of the progestin R5020 and the antiprogestin RU486 on the growth of the MCF-7 and T47D breast cancer cell lines. Differences between the two compounds were demonstrated in several parameters. 1. Estradiol was required for the efficient inhibition of cell growth of both lines by R5020 but not by RU486. Therefore in the total absence of estrogen (phenol-red free medium), the effects of the two drugs on cell growth were dissociated, RU486 remaining inhibitory while R5020 was inactive. 2. The proteins secreted by cells were differently affected, since R5020 induced a 48K protein and decreased the production of the estrogen-regulated 52K protein, while RU486 had no effect on these two parameters. 3. The morphology of cells treated by R5020 was more altered in the presence of estradiol than in its absence, while that of cells treated by RU486 was not affected whether or not estradiol was present. 4. There was a greater reduction of estrogen receptor sites in MCF-7 cells produced by R5020 than by RU486. Even though the two drugs appear to act through the same progesterone receptor and to inhibit total protein secretion, it is likely that they exert their antiproliferative effects on cultured breast cancer cells by different mechanisms. R5020 antagonizes the stimulation produced by estradiol. RU486 by contrast exerts a more direct progesterone receptor mediated inhibitory effect requiring no synergism by estradiol and therefore does not act through a partial progestin activity.

Url:

https://api.istex.fr/document/A0075C6D840A104E3B7DE3CDB1B824FDD9919626/fulltext/pdf

DOI: 10.1007/BF01806133

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: 001E24
to stream Istex, to step Curation: 001E24
to stream Istex, to step Checkpoint: 002D88
to stream Main, to step Merge: 00F190
to stream Main, to step Curation: 00DF54

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells</title>
<author><name sortKey="Gill, P G" sort="Gill, P G" uniqKey="Gill P" first="P. G." last="Gill">P. G. Gill</name>
</author>
<author><name sortKey="Vignon, F" sort="Vignon, F" uniqKey="Vignon F" first="F." last="Vignon">F. Vignon</name>
</author>
<author><name sortKey="Bardon, S" sort="Bardon, S" uniqKey="Bardon S" first="S." last="Bardon">S. Bardon</name>
</author>
<author><name sortKey="Derocq, D" sort="Derocq, D" uniqKey="Derocq D" first="D." last="Derocq">D. Derocq</name>
</author>
<author><name sortKey="Rochefort, H" sort="Rochefort, H" uniqKey="Rochefort H" first="H." last="Rochefort">H. Rochefort</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:A0075C6D840A104E3B7DE3CDB1B824FDD9919626</idno>
<date when="1987" year="1987">1987</date>
<idno type="doi">10.1007/BF01806133</idno>
<idno type="url">https://api.istex.fr/document/A0075C6D840A104E3B7DE3CDB1B824FDD9919626/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001E24</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001E24</idno>
<idno type="wicri:Area/Istex/Curation">001E24</idno>
<idno type="wicri:Area/Istex/Checkpoint">002D88</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002D88</idno>
<idno type="wicri:doubleKey">0167-6806:1987:Gill P:difference:between:r</idno>
<idno type="wicri:Area/Main/Merge">00F190</idno>
<idno type="wicri:Area/Main/Curation">00DF54</idno>
<idno type="wicri:Area/Main/Exploration">00DF54</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells</title>
<author><name sortKey="Gill, P G" sort="Gill, P G" uniqKey="Gill P" first="P. G." last="Gill">P. G. Gill</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Institut national de la Sante et de la Recherche Medicale, Inserm U148, 60 rue de Navacelles, 34100, Montpellier</wicri:regionArea>
<placeName><region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Centre de Biochimie du CNRS, Faculté des Sciences, Parc Valrose, 06034, Nice Cédex</wicri:regionArea>
<wicri:noRegion>06034, Nice Cédex</wicri:noRegion>
<wicri:noRegion>Nice Cédex</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Vignon, F" sort="Vignon, F" uniqKey="Vignon F" first="F." last="Vignon">F. Vignon</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Institut national de la Sante et de la Recherche Medicale, Inserm U148, 60 rue de Navacelles, 34100, Montpellier</wicri:regionArea>
<placeName><region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bardon, S" sort="Bardon, S" uniqKey="Bardon S" first="S." last="Bardon">S. Bardon</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Institut national de la Sante et de la Recherche Medicale, Inserm U148, 60 rue de Navacelles, 34100, Montpellier</wicri:regionArea>
<placeName><settlement type="city">Montpellier</settlement>
<region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Languedoc-Roussillon</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Australie</country>
<wicri:regionArea>Department of Surgery, Royal Adelaide Hospital, The University of Adélaide, 5000, Adelaide — South Australia</wicri:regionArea>
<wicri:noRegion>Adelaide — South Australia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Derocq, D" sort="Derocq, D" uniqKey="Derocq D" first="D." last="Derocq">D. Derocq</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Institut national de la Sante et de la Recherche Medicale, Inserm U148, 60 rue de Navacelles, 34100, Montpellier</wicri:regionArea>
<placeName><settlement type="city">Montpellier</settlement>
<region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Languedoc-Roussillon</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rochefort, H" sort="Rochefort, H" uniqKey="Rochefort H" first="H." last="Rochefort">H. Rochefort</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Institut national de la Sante et de la Recherche Medicale, Inserm U148, 60 rue de Navacelles, 34100, Montpellier</wicri:regionArea>
<placeName><settlement type="city">Montpellier</settlement>
<region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Languedoc-Roussillon</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Breast Cancer Research and Treatment</title>
<title level="j" type="abbrev">Breast Cancer Res Tr</title>
<idno type="ISSN">0167-6806</idno>
<idno type="eISSN">1573-7217</idno>
<imprint><publisher>Martinus Nijhoff/Dr. W. Junk Publishers</publisher>
<pubPlace>Dordrecht</pubPlace>
<date type="published" when="1987-10-01">1987-10-01</date>
<biblScope unit="volume">10</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="37">37</biblScope>
<biblScope unit="page" to="45">45</biblScope>
</imprint>
<idno type="ISSN">0167-6806</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0167-6806</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiestrogenic effect</term>
<term>Antiprogestin</term>
<term>Antiproliferative</term>
<term>Antiproliferative activity</term>
<term>Antiproliferative effect</term>
<term>Antiproliferative effects</term>
<term>Assay</term>
<term>Bardon</term>
<term>Biol chem</term>
<term>Breast cancer</term>
<term>Breast cancer cell line</term>
<term>Breast cancer cell lines</term>
<term>Breast cancer cells</term>
<term>Cell endocrinol</term>
<term>Cell growth</term>
<term>Cell growth inhibition</term>
<term>Cell lines</term>
<term>Cell proliferation</term>
<term>Clin endocrinol metab</term>
<term>Complete absence</term>
<term>Culture media</term>
<term>Culture medium</term>
<term>Cultured breast cancer cells</term>
<term>Cultured cells</term>
<term>Current address</term>
<term>Different mechanisms</term>
<term>Differential effect</term>
<term>Elisa technique</term>
<term>Estradiol</term>
<term>Estrogen</term>
<term>Estrogen receptor</term>
<term>Estrogen receptor content</term>
<term>Estrogen receptor sites</term>
<term>Glucocorticoid antagonist</term>
<term>Growth factors</term>
<term>Human breast cancer</term>
<term>Human breast cancer cell line</term>
<term>Human breast cancer cells</term>
<term>Mcf7 breast cancer cells</term>
<term>Partial progestin activity</term>
<term>Phase contrast</term>
<term>Phenol</term>
<term>Proc natl acad</term>
<term>Progesterone</term>
<term>Progesterone receptor</term>
<term>Progestin</term>
<term>Protein synthesis</term>
<term>Receptor</term>
<term>Recherche medicale</term>
<term>Rochefort</term>
<term>Same progesterone receptor</term>
<term>Steroid</term>
<term>Total protein</term>
<term>Total protein synthesis</term>
<term>Total proteins</term>
<term>Vignon</term>
<term>Weak estrogen</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Antiestrogenic effect</term>
<term>Antiprogestin</term>
<term>Antiproliferative</term>
<term>Antiproliferative activity</term>
<term>Antiproliferative effect</term>
<term>Antiproliferative effects</term>
<term>Assay</term>
<term>Bardon</term>
<term>Biol chem</term>
<term>Breast cancer</term>
<term>Breast cancer cell line</term>
<term>Breast cancer cell lines</term>
<term>Breast cancer cells</term>
<term>Cell endocrinol</term>
<term>Cell growth</term>
<term>Cell growth inhibition</term>
<term>Cell lines</term>
<term>Cell proliferation</term>
<term>Clin endocrinol metab</term>
<term>Complete absence</term>
<term>Culture media</term>
<term>Culture medium</term>
<term>Cultured breast cancer cells</term>
<term>Cultured cells</term>
<term>Current address</term>
<term>Different mechanisms</term>
<term>Differential effect</term>
<term>Elisa technique</term>
<term>Estradiol</term>
<term>Estrogen</term>
<term>Estrogen receptor</term>
<term>Estrogen receptor content</term>
<term>Estrogen receptor sites</term>
<term>Glucocorticoid antagonist</term>
<term>Growth factors</term>
<term>Human breast cancer</term>
<term>Human breast cancer cell line</term>
<term>Human breast cancer cells</term>
<term>Mcf7 breast cancer cells</term>
<term>Partial progestin activity</term>
<term>Phase contrast</term>
<term>Phenol</term>
<term>Proc natl acad</term>
<term>Progesterone</term>
<term>Progesterone receptor</term>
<term>Progestin</term>
<term>Protein synthesis</term>
<term>Receptor</term>
<term>Recherche medicale</term>
<term>Rochefort</term>
<term>Same progesterone receptor</term>
<term>Steroid</term>
<term>Total protein</term>
<term>Total protein synthesis</term>
<term>Total proteins</term>
<term>Vignon</term>
<term>Weak estrogen</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Summary: We have compared the effects of the progestin R5020 and the antiprogestin RU486 on the growth of the MCF-7 and T47D breast cancer cell lines. Differences between the two compounds were demonstrated in several parameters. 1. Estradiol was required for the efficient inhibition of cell growth of both lines by R5020 but not by RU486. Therefore in the total absence of estrogen (phenol-red free medium), the effects of the two drugs on cell growth were dissociated, RU486 remaining inhibitory while R5020 was inactive. 2. The proteins secreted by cells were differently affected, since R5020 induced a 48K protein and decreased the production of the estrogen-regulated 52K protein, while RU486 had no effect on these two parameters. 3. The morphology of cells treated by R5020 was more altered in the presence of estradiol than in its absence, while that of cells treated by RU486 was not affected whether or not estradiol was present. 4. There was a greater reduction of estrogen receptor sites in MCF-7 cells produced by R5020 than by RU486. Even though the two drugs appear to act through the same progesterone receptor and to inhibit total protein secretion, it is likely that they exert their antiproliferative effects on cultured breast cancer cells by different mechanisms. R5020 antagonizes the stimulation produced by estradiol. RU486 by contrast exerts a more direct progesterone receptor mediated inhibitory effect requiring no synergism by estradiol and therefore does not act through a partial progestin activity.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>France</li>
</country>
<region><li>Languedoc-Roussillon</li>
<li>Occitanie (région administrative)</li>
</region>
<settlement><li>Montpellier</li>
</settlement>
</list>
<tree><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Gill, P G" sort="Gill, P G" uniqKey="Gill P" first="P. G." last="Gill">P. G. Gill</name>
</region>
<name sortKey="Bardon, S" sort="Bardon, S" uniqKey="Bardon S" first="S." last="Bardon">S. Bardon</name>
<name sortKey="Derocq, D" sort="Derocq, D" uniqKey="Derocq D" first="D." last="Derocq">D. Derocq</name>
<name sortKey="Gill, P G" sort="Gill, P G" uniqKey="Gill P" first="P. G." last="Gill">P. G. Gill</name>
<name sortKey="Rochefort, H" sort="Rochefort, H" uniqKey="Rochefort H" first="H." last="Rochefort">H. Rochefort</name>
<name sortKey="Vignon, F" sort="Vignon, F" uniqKey="Vignon F" first="F." last="Vignon">F. Vignon</name>
</country>
<country name="Australie"><noRegion><name sortKey="Bardon, S" sort="Bardon, S" uniqKey="Bardon S" first="S." last="Bardon">S. Bardon</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00DF54 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00DF54 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:A0075C6D840A104E3B7DE3CDB1B824FDD9919626
   |texte=   Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells

Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri